THERAtRAME
THERAtRAME discovers and develops small molecules targeting tRNA epitranscriptomics to treat cancer patients with immune-refractory and resistant tumors.
THERAtRAME discovers and develops first-in-class small molecules targeting tRNA epitranscriptomics for cancer patients. The company's proprietary platform targets tRNA modifications to develop therapies for immune-refractory and target-therapy resistant tumors. Their investment plan focuses on advancing their lead program into clinical development while strengthening their platform and biomarker capabilities.
Key People
Francesca RAPINO - Co-Founder